InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: None

Friday, 12/21/2012 11:05:09 AM

Friday, December 21, 2012 11:05:09 AM

Post# of 1166
approved $5.20 now

Chembio Diagnostics receives FDA approval for DPP Point-of-Care HIV 1/2 rapid test (CEMI) 4.60 : Co announces receipt of approval from the FDA to market the Company's Dual Path Platform HIV 1/2 assay for the rapid, point-of-care (POC) detection of HIV-1/2 antibodies in either oral fluid or blood samples. This determination follows a review of Chembio's Premarket Approval application and marks the first FDA approval of a diagnostic assay utilizing the Company's patented Dual Path Platform? technology. DPP enables samples to bind directly with target analytes before detection reagents are introduced to visualize the test results, and can improve accuracy compared with the current lateral flow HIV test technologies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y